The Experts below are selected from a list of 300 Experts worldwide ranked by ideXlab platform
Brian R Leaker - One of the best experts on this subject based on the ideXlab platform.
-
the effects of the selective muscarinic m3 receptor antagonist darifenacin and of hyoscine scopolamine on motion sickness skin conductance cognitive function
British Journal of Clinical Pharmacology, 2018Co-Authors: John F Golding, Keith Wesnes, Brian R LeakerAbstract:Aims: The aim of this study was to compare the effects of the selective M3 muscarinic acetylcholine receptor antagonist Darifenacin, oral Hyoscine Hydrobromide and Placebo on motion sickness induced by cross-coupled stimulation. Methods: The effects of Darifenacin 10 mg or 20 mg, Hyoscine Hydrobromide 0.6 mg and Placebo were assessed in a randomised, double-blind, 4-way cross over trial of 16 healthy subjects. Motion sickness, skin conductance (a measure of sweating) and psychomotor cognitive function tests were investigated. Results: Hyoscine Hydrobromide produced significantly increased tolerance to motion versus Placebo (P<0.05 to P<0.01). The motion protection effect of Darifenacin (10 or 20 mg) was approximately one third of that of Hyoscine Hydrobromide, but was not significant versus Placebo. Darifenacin and Hyoscine Hydrobromide both significantly reduced skin conductance versus Placebo. Darifenacin produced either no effect or an enhanced effect on cognitive function in contrast to Hyoscine Hydrobromide where there was significant impairment of psychomotor performance. Conclusion: The results suggest that selective antagonism of the M3 receptor may not be important in the prevention of motion sickness. However selective M3 antagonism does not impair cognitive function. These observations may be important given that long term treatment with non-selective anti-muscarinic agents such as Oxybutynin may lead to an increased incidence of dementia.
-
The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
British journal of clinical pharmacology, 2018Co-Authors: John F Golding, Keith Wesnes, Brian R LeakerAbstract:Aims: The aim of this study was to compare the effects of the selective M3 muscarinic acetylcholine receptor antagonist Darifenacin, oral Hyoscine Hydrobromide and Placebo on motion sickness induced by cross-coupled stimulation. Methods: The effects of Darifenacin 10 mg or 20 mg, Hyoscine Hydrobromide 0.6 mg and Placebo were assessed in a randomised, double-blind, 4-way cross over trial of 16 healthy subjects. Motion sickness, skin conductance (a measure of sweating) and psychomotor cognitive function tests were investigated. Results: Hyoscine Hydrobromide produced significantly increased tolerance to motion versus Placebo (P
John F Golding - One of the best experts on this subject based on the ideXlab platform.
-
the effects of the selective muscarinic m3 receptor antagonist darifenacin and of hyoscine scopolamine on motion sickness skin conductance cognitive function
British Journal of Clinical Pharmacology, 2018Co-Authors: John F Golding, Keith Wesnes, Brian R LeakerAbstract:Aims: The aim of this study was to compare the effects of the selective M3 muscarinic acetylcholine receptor antagonist Darifenacin, oral Hyoscine Hydrobromide and Placebo on motion sickness induced by cross-coupled stimulation. Methods: The effects of Darifenacin 10 mg or 20 mg, Hyoscine Hydrobromide 0.6 mg and Placebo were assessed in a randomised, double-blind, 4-way cross over trial of 16 healthy subjects. Motion sickness, skin conductance (a measure of sweating) and psychomotor cognitive function tests were investigated. Results: Hyoscine Hydrobromide produced significantly increased tolerance to motion versus Placebo (P<0.05 to P<0.01). The motion protection effect of Darifenacin (10 or 20 mg) was approximately one third of that of Hyoscine Hydrobromide, but was not significant versus Placebo. Darifenacin and Hyoscine Hydrobromide both significantly reduced skin conductance versus Placebo. Darifenacin produced either no effect or an enhanced effect on cognitive function in contrast to Hyoscine Hydrobromide where there was significant impairment of psychomotor performance. Conclusion: The results suggest that selective antagonism of the M3 receptor may not be important in the prevention of motion sickness. However selective M3 antagonism does not impair cognitive function. These observations may be important given that long term treatment with non-selective anti-muscarinic agents such as Oxybutynin may lead to an increased incidence of dementia.
-
The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
British journal of clinical pharmacology, 2018Co-Authors: John F Golding, Keith Wesnes, Brian R LeakerAbstract:Aims: The aim of this study was to compare the effects of the selective M3 muscarinic acetylcholine receptor antagonist Darifenacin, oral Hyoscine Hydrobromide and Placebo on motion sickness induced by cross-coupled stimulation. Methods: The effects of Darifenacin 10 mg or 20 mg, Hyoscine Hydrobromide 0.6 mg and Placebo were assessed in a randomised, double-blind, 4-way cross over trial of 16 healthy subjects. Motion sickness, skin conductance (a measure of sweating) and psychomotor cognitive function tests were investigated. Results: Hyoscine Hydrobromide produced significantly increased tolerance to motion versus Placebo (P
Keith Wesnes - One of the best experts on this subject based on the ideXlab platform.
-
the effects of the selective muscarinic m3 receptor antagonist darifenacin and of hyoscine scopolamine on motion sickness skin conductance cognitive function
British Journal of Clinical Pharmacology, 2018Co-Authors: John F Golding, Keith Wesnes, Brian R LeakerAbstract:Aims: The aim of this study was to compare the effects of the selective M3 muscarinic acetylcholine receptor antagonist Darifenacin, oral Hyoscine Hydrobromide and Placebo on motion sickness induced by cross-coupled stimulation. Methods: The effects of Darifenacin 10 mg or 20 mg, Hyoscine Hydrobromide 0.6 mg and Placebo were assessed in a randomised, double-blind, 4-way cross over trial of 16 healthy subjects. Motion sickness, skin conductance (a measure of sweating) and psychomotor cognitive function tests were investigated. Results: Hyoscine Hydrobromide produced significantly increased tolerance to motion versus Placebo (P<0.05 to P<0.01). The motion protection effect of Darifenacin (10 or 20 mg) was approximately one third of that of Hyoscine Hydrobromide, but was not significant versus Placebo. Darifenacin and Hyoscine Hydrobromide both significantly reduced skin conductance versus Placebo. Darifenacin produced either no effect or an enhanced effect on cognitive function in contrast to Hyoscine Hydrobromide where there was significant impairment of psychomotor performance. Conclusion: The results suggest that selective antagonism of the M3 receptor may not be important in the prevention of motion sickness. However selective M3 antagonism does not impair cognitive function. These observations may be important given that long term treatment with non-selective anti-muscarinic agents such as Oxybutynin may lead to an increased incidence of dementia.
-
The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
British journal of clinical pharmacology, 2018Co-Authors: John F Golding, Keith Wesnes, Brian R LeakerAbstract:Aims: The aim of this study was to compare the effects of the selective M3 muscarinic acetylcholine receptor antagonist Darifenacin, oral Hyoscine Hydrobromide and Placebo on motion sickness induced by cross-coupled stimulation. Methods: The effects of Darifenacin 10 mg or 20 mg, Hyoscine Hydrobromide 0.6 mg and Placebo were assessed in a randomised, double-blind, 4-way cross over trial of 16 healthy subjects. Motion sickness, skin conductance (a measure of sweating) and psychomotor cognitive function tests were investigated. Results: Hyoscine Hydrobromide produced significantly increased tolerance to motion versus Placebo (P
-
effect of galantamine Hydrobromide in chronic fatigue syndrome a randomized controlled trial
JAMA, 2004Co-Authors: C Russell V Blacker, Keith Wesnes, David T Greenwood, Rosamund Wilson, Carol Woodward, Ian Howe, Tauhid AliAbstract:ContextThere is no established pharmacological treatment for the core symptoms of chronic fatigue syndrome (CFS). Galantamine Hydrobromide, an acetyl cholesterone inhibitor, has pharmacological properties that might benefit patients with CFS.ObjectiveTo compare the efficacy and tolerability of galantamine Hydrobromide in patients with CFS.Design, Setting, and PatientsRandomized, double-blind trial conducted June 1997 through July 1999 at 35 outpatient centers in the United Kingdom (n = 17), United States (n = 14), the Netherlands (n = 2), Sweden (n = 1), and Belgium (n = 1) involving 434 patients with a clinical diagnosis of CFS (modified US Centers for Disease Control and Prevention criteria).InterventionsA total of 89 patients were randomly assigned to receive 2.5 mg of galantamine Hydrobromide; 86 patients, 5.0 mg; 91 patients, 7.5 mg; and 86 patients, 10 mg (these patients received medicine in the tablet form 3 times per day); a total of 82 patients received matching placebo tablets 3 times per day.Main Outcome MeasuresThe primary efficacy variable was the global change on the Clinician Global Impression Scale after 4, 8, 12, and 16 weeks of treatment. Secondary outcomes were changes in core symptoms of CFS on the Chalder Fatigue Rating Scale, the Fibromyalgia Impact Questionnaire, and the Pittsburgh Sleep Quality Index; changes in quality of life on the Nottingham Health Profile; and assessment of plasma-free cortisol levels and cognitive performance on a computer-based battery of tests.ResultsAfter 16 weeks, there were no statistically significant differences between any of the galantamine or placebo groups in clinical condition on the Clinician Global Impression Scale, or for any of the secondary end points. Exploratory regression analysis failed to detect any consistent prognostic factor that might have influenced the primary or any secondary outcome measures.ConclusionThis trial did not demonstrate any benefit of galantamine over placebo in the treatment of patients with CFS.
Shinsei Sayama - One of the best experts on this subject based on the ideXlab platform.
-
a convenient synthesis of oxazolines and imidazolines from aromatic aldehydes with pyridinium Hydrobromide perbromide in water
Synlett, 2006Co-Authors: Shinsei SayamaAbstract:Various 2-oxazolines were prepared from aromatic aldehydes and 2-aminoethanol with pyridinium Hydrobromide perbromide in water at room temperature. 2-Imidazolines were also obtained in good yields from aromatic aldehydes and ethylenediamine under the same reaction conditions.
-
esterification of aldehydes and alcohols with pyridinium Hydrobromide perbromide in water
Synlett, 2004Co-Authors: Shinsei Sayama, Tetsuo OnamiAbstract:The direct esterification of aldehydes and alcohols was carried out with pyridinium Hydrobromide perbromide in water at room temperature. A variety of aldehydes were converted to respective ester derivatives with alcoholssuch as methanol, 1,2-ethanediol, 1,3-propanediol. Further, a variety of aliphatic alcohols were also converted to the corresponding Tishchenko-like dimeric esters in good yields under the same reaction conditions.
Tetsuo Onami - One of the best experts on this subject based on the ideXlab platform.
-
esterification of aldehydes and alcohols with pyridinium Hydrobromide perbromide in water
Synlett, 2004Co-Authors: Shinsei Sayama, Tetsuo OnamiAbstract:The direct esterification of aldehydes and alcohols was carried out with pyridinium Hydrobromide perbromide in water at room temperature. A variety of aldehydes were converted to respective ester derivatives with alcoholssuch as methanol, 1,2-ethanediol, 1,3-propanediol. Further, a variety of aliphatic alcohols were also converted to the corresponding Tishchenko-like dimeric esters in good yields under the same reaction conditions.
